Dazhong Lv

Oncofusion Therapeutics, Inc. operates as oncology development company. It specializes in BET Bromodomain Inhibitors, ERG Inhibitors, EZH2-EED Inhibitors and MMSET/NSD2 Inhibitors. The company was founded in 2012 by Arul M. Chinnaiyan and Shaomeng Wang and is headquartered in Ann Arbor, MI.

Peking University provides post-secondary education services. It offers undergraduate and graduate courses. It provides courses such as basic and applied sciences, social sciences and the humanities, sciences of medicine, management, and education. The company was founded by JiaNai Sun in 1898 and is headquartered in Beijing, China.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Beijing SinceTimes Communication Co., Ltd. develops mobile application software solutions. The company is headquartered in Beijing, China.

EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016.

Oncopia Therapeutics LLC engages in biotechnology research. The company was founded in 2017 and is headquartered in Malvern, PA.

Medsyn Biopharma LLC develops therapeutics for cancer. The company was founded by Shaomeng Wang and is headquartered in Malvern, PA.

Part of University of Michigan, Rogel Cancer Center provides healthcare services for cancer patients.

Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients.

Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group Corp. Ltd. is a Chinese biopharmaceutical company. The company is based in Hong Kong, Hong Kong. The company was founded by Shao Meng Wang.